A randomized phase II trial (NCT01126879) determined whether treatment with genistein could reduce the number of circulating prostate cancer cells and tumor growth via the downregulation of the expression of factors promoting tumor growth, including MMP-2, in prostate tissue. The gene discussed is MMP2; the disease is neoplasm.